Minghua Li - SHANDONG LUOXIN CEO
CEO
Ms. Li Minghua is Executive Director, General Manager, Chief Executive Officer and Head Research and Development at Shandong Luoxin Pharmacy Stock Co Ltd. She is responsible for assisting the Chairman of the Company in the Companys overall business development and operation. She graduated from Shenyang Pharmacy University with a bachelors degree in Pharmacy. Ms. Li is a senior professional engineer in medicine in the PRC certified by Hei Long Jiang Human Resource Department and a registered practising pharmacist. Before joining the Company in 2001, Ms. Li had over 15 years experience working in several pharmaceutical enterprises in the PRC. Ms. Li was granted the Qi Lu Female Inventor award in 2010. She is a delegate of the Fei County Peoples Congress. Ms. Li is currently a director of Shandong Yuxin Pharmacy Company Limited. since 2013.
| Age | 48 |
| Tenure | 11 years |
| Phone | 86 53 9824 1226 |
| Web | http://www.luoxin.cn |
SHANDONG LUOXIN Management Efficiency
The company has return on total asset (ROA) of 8.17 % which means that it generated a profit of $8.17 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 12.54 %, meaning that it generated $12.54 on every $100 dollars invested by stockholders. SHANDONG LUOXIN's management efficiency ratios could be used to measure how well SHANDONG LUOXIN manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | CEO Age | ||
| Albert Carey | PepsiCo | 66 | |
| Ramon Laguarta | PepsiCo | 60 | |
| Patrick Goepel | Asure Software | 62 | |
| Masamichi Terabatake | Japan Tobacco ADR | 58 | |
| Michael Spanos | PepsiCo | 53 | |
| Mitsuomi Koizumi | Japan Tobacco ADR | 59 | |
| David Fox | Q2 Holdings | 45 | |
| Matthew Flake | Q2 Holdings | 52 | |
| Laxman Narasimhan | PepsiCo | 50 | |
| Sanjeev Chadha | PepsiCo | 57 | |
| Mike Spanos | PepsiCo | 52 | |
Management Performance
| Return On Equity | 12.54 | |||
| Return On Asset | 8.17 |
SHANDONG LUOXIN PHRM Leadership Team
Elected by the shareholders, the SHANDONG LUOXIN's board of directors comprises two types of representatives: SHANDONG LUOXIN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SHANDONG. The board's role is to monitor SHANDONG LUOXIN's management team and ensure that shareholders' interests are well served. SHANDONG LUOXIN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SHANDONG LUOXIN's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guanhua Du, Independent Non-Executive Director | ||
| Zhenhai Liu, Non-Executive Director | ||
| Yun Chen, Independent Non-Executive Director | ||
| Zhenteng Liu, Executive Director | ||
| Baoqi Liu, Chairman and Compliance Officer | ||
| Yu Chen, Vice General Manager of Production Department and Executive Director | ||
| Tin Foo, Independent Non-Executive Director | ||
| Hongzheng Fu, Independent Non-Executive Director | ||
| Chuangui Yin, Non-Executive Director | ||
| Fengsheng Han, Secretary of the Board and Executive Director | ||
| Minghua Li, CEO, Head of RandD Department, General Manager and Executive Director | ||
| Hon Lau, Financial Controller, Company Secretary |
SHANDONG Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is SHANDONG LUOXIN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 12.54 | |||
| Return On Asset | 8.17 | |||
| Profit Margin | 7.86 % | |||
| Operating Margin | 7.38 % | |||
| Current Valuation | 601.93 M | |||
| Shares Outstanding | 609.6 M | |||
| Price To Earning | 3.10 X | |||
| Price To Book | 2.27 X | |||
| Price To Sales | 1.99 X | |||
| Revenue | 646.45 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in SHANDONG Pink Sheet
If you are still planning to invest in SHANDONG LUOXIN PHRM check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SHANDONG LUOXIN's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |